Gyre Therapeutics (GYRE) Expected to Announce Quarterly Earnings on Monday

Key Points

• Gyre Therapeutics is expected to report Q4 2025 results before the market opens on Monday, March 16, with analysts forecasting EPS $0.08 and revenue $36.3M; the company will host an earnings call on March 19 at 4:00 PM ET.
• Shares opened at $7.71 and were down about 1.5%; the firm has a market cap of $742.7M and a P/E of 257.1, and Wall Street's consensus rating is a Hold with an average target price of $17.00.
• Gyre is a clinical‑stage biotech developing small‑molecule, lipid‑targeted therapies for NASH, Alzheimer's and autoimmune diseases, and institutional investors own roughly 24% of the stock after recent position increases by several funds.

Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Monday, March 16th. Analysts expect the company to announce earnings of $0.08 per share and revenue of $36.3030 million for the quarter. Investors may visit the the company's upcoming Q4 2025 earning results page for the latest details on the call scheduled for Thursday, March 19, 2026 at 4:00 PM ET.

Gyre Therapeutics Trading Down 1.5%

Shares of GYRE stock opened at $7.71 on Monday. The firm's 50 day moving average is $7.87 and its 200 day moving average is $7.78. The stock has a market capitalization of $742.70 million, a P/E ratio of 257.09 and a beta of 1.97. Gyre Therapeutics has a 12 month low of $6.11 and a 12 month high of $13.75.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on GYRE. Zacks Research raised shares of Gyre Therapeutics from a "strong sell" rating to a "hold" rating in a report on Friday, November 14th. Weiss Ratings reaffirmed a "sell (d)" rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Finally, Wall Street Zen upgraded Gyre Therapeutics from a "hold" rating to a "buy" rating in a research report on Saturday, November 15th. Three equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Hold" and an average target price of $17.00.

Hedge Funds Weigh In On Gyre Therapeutics

Several hedge funds have recently bought and sold shares of the company. Bank of America Corp DE increased its holdings in Gyre Therapeutics by 28.8% during the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company's stock worth $46,000 after acquiring an additional 1,402 shares during the period. Alliancebernstein L.P. boosted its holdings in Gyre Therapeutics by 9.5% in the 3rd quarter. Alliancebernstein L.P. now owns 21,830 shares of the company's stock valued at $163,000 after purchasing an additional 1,900 shares during the period. JPMorgan Chase & Co. boosted its holdings in Gyre Therapeutics by 84.6% in the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company's stock valued at $47,000 after purchasing an additional 2,961 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Gyre Therapeutics by 77.8% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company's stock valued at $54,000 after purchasing an additional 3,244 shares in the last quarter. Finally, Barclays PLC grew its position in shares of Gyre Therapeutics by 38.3% during the 4th quarter. Barclays PLC now owns 18,531 shares of the company's stock valued at $131,000 after purchasing an additional 5,135 shares in the last quarter. Hedge funds and other institutional investors own 23.99% of the company's stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.